01577nas a2200181   4500000000100000008004100001260001500042100001400057700001800071700001400089700001700103245009800120856007200218300001100290490000600301520107400307022001401381       2025                            d  c2025-09-161 aAna Kojic1 aJavid Moslehi1 aBonnie Ky1 aJoseph C. Wu00aCardiometabolic disease and cardio-oncology: Insights from iPSC models and tissue engineering  uhttps://www.sciencedirect.com/science/article/pii/S2666379125003349  a1022610 v63 aHeart disease and cancer share common risk factors, genetic predispositions, and metabolic and inflammatory components. Metabolic reprogramming can drive disease progression in both, with cardiometabolic syndrome—marked by obesity, insulin resistance, dyslipidemia, and hypertension—contributing to cancer development. Studies link around 20% of cancer cases to obesity, while elevated glucose and triglyceride levels increase the risk of liver, thyroid, and respiratory cancers. Beyond treatment-related cardiotoxicity, cancer patients often have pre-existing cardiovascular disease (CVD) at diagnosis, highlighting their bidirectional relationship. Patient-specific induced pluripotent stem cells (iPSCs) offer a powerful platform to study these links at a personalized level. iPSC models help explore shared molecular mechanisms, metabolic dysregulation, inflammation, and cardiotoxicity. This review examines emerging themes in cardio-oncology and cardio-metabolism, emphasizing how iPSC-based approaches can reveal disease connections and inform new therapies.  a2666-3791